Adaptive Biotechnologies (ADPT) 10-Q 2 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Trading Symbol	ADPT
Entity Registrant Name	ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key	0001478320
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		144,645,118
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity File Number	001-38957
Entity Tax Identification Number	27-0907024
Entity Address, Address Line One	1165 Eastlake Avenue East
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98109
City Area Code	(206)
Local Phone Number	659-0067
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	WA

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 109,240	$ 90,030
Short-term marketable securities (amortized cost of $308,885 and $412,282, respectively)	307,990	408,166
Accounts receivable, net	31,545	40,057
Inventory	18,960	14,453
Prepaid expenses and other current assets	9,074	9,440
Total current assets	476,809	562,146
Long-term assets
Property and equipment, net	79,390	83,447
Operating lease right-of-use assets	77,109	80,763
Restricted cash	2,923	2,398
Intangible assets, net	5,985	6,827
Goodwill	118,972	118,972
Other assets	3,352	2,064
Total assets	764,540	856,617
Current liabilities
Accounts payable	9,163	8,084
Accrued liabilities	8,356	12,424
Accrued compensation and benefits	10,554	15,935
Current portion of operating lease liabilities	9,345	9,230
Current portion of deferred revenue	57,917	64,115
Total current liabilities	95,335	109,788
Long-term liabilities
Operating lease liabilities, less current portion	94,176	98,772
Deferred revenue, less current portion	50,895	58,599
Revenue interest liability, net	128,167	125,360
Total liabilities	368,573	392,519
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2023 and December 31, 2022; 144,645,118 and 143,105,002 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	14	14
Additional paid-in capital	1,421,506	1,387,349
Accumulated other comprehensive loss	(893)	(4,116)
Accumulated deficit	(1,024,591)	(919,082)
Total Adaptive Biotechnologies Corporation shareholders’ equity	396,036	464,165
Noncontrolling interest	(69)	(67)
Total shareholders’ equity	395,967	464,098
Total liabilities and shareholders’ equity	$ 764,540	$ 856,617

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Amortized cost of short-term marketable securities	$ 308,885	$ 412,282
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock authorized	10,000,000	10,000,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Common stock par value	$ 0.0001	$ 0.0001
Common stock authorized	340,000,000	340,000,000
Common stock issued	144,645,118	143,105,002
Common stock outstanding	144,645,118	143,105,002

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue	$ 48,926	$ 43,660	$ 86,573	$ 82,280
Operating expenses
Cost of revenue	17,910	13,221	36,591	26,413
Research and development	32,237	37,037	64,838	74,876
Sales and marketing	23,872	24,281	46,180	50,374
General and administrative	22,302	21,200	43,133	45,344
Amortization of intangible assets	423	423	842	842
Total operating expenses	96,744	96,162	191,584	197,849
Loss from operations	(47,818)	(52,502)	(105,011)	(115,569)
Interest and other income, net	3,612	418	6,636	689
Interest expense	(3,605)		(7,136)
Net loss	(47,811)	(52,084)	(105,511)	(114,880)
Add: Net loss attributable to noncontrolling interest	1	38	2	98
Net loss attributable to Adaptive Biotechnologies Corporation	$ (47,810)	$ (52,046)	$ (105,509)	$ (114,782)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	$ (0.33)	$ (0.37)	$ (0.73)	$ (0.81)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	144,397,693	142,363,589	143,956,867	142,032,261
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	$ (0.33)	$ (0.37)	$ (0.73)	$ (0.81)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	144,397,693	142,363,589	143,956,867	142,032,261

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (47,811)	$ (52,084)	$ (105,511)	$ (114,880)
Other comprehensive income (loss)
Change in unrealized gains and losses on investments	1,012	(1,017)	3,223	(4,663)
Comprehensive loss	(46,799)	(53,101)	(102,288)	(119,543)
Add: Comprehensive loss attributable to noncontrolling interest	1	38	2	98
Comprehensive loss attributable to Adaptive Biotechnologies Corporation	$ (46,798)	$ (53,063)	$ (102,286)	$ (119,445)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interest
Beginning Balance at Dec. 31, 2021	$ 604,102	$ 14	$ 1,324,006	$ (1,137)	$ (718,891)	$ 110
Beginning Balance, Shares at Dec. 31, 2021		141,393,865
Issuance of common stock for cash upon exercise of stock options	6,716		6,716
Issuance of common stock for cash upon exercise of stock options, Shares		1,230,089
Vesting of restricted stock units		160,914
Share-based compensation expense	27,041		27,041
Other comprehensive income (loss)	(4,663)			(4,663)
Net loss	(114,880)				(114,782)	(98)
Ending Balance at Jun. 30, 2022	518,316	$ 14	1,357,763	(5,800)	(833,673)	12
Ending Balance, Shares at Jun. 30, 2022		142,784,868
Beginning Balance at Mar. 31, 2022	553,255	$ 14	1,339,601	(4,783)	(781,627)	50
Beginning Balance, Shares at Mar. 31, 2022		142,183,258
Issuance of common stock for cash upon exercise of stock options	3,982		3,982
Issuance of common stock for cash upon exercise of stock options, Shares		581,881
Vesting of restricted stock units		19,729
Share-based compensation expense	14,180		14,180
Other comprehensive income (loss)	(1,017)			(1,017)
Net loss	(52,084)				(52,046)	(38)
Ending Balance at Jun. 30, 2022	518,316	$ 14	1,357,763	(5,800)	(833,673)	12
Ending Balance, Shares at Jun. 30, 2022		142,784,868
Beginning Balance at Dec. 31, 2022	464,098	$ 14	1,387,349	(4,116)	(919,082)	(67)
Beginning Balance, Shares at Dec. 31, 2022		143,105,002
Issuance of common stock for cash upon exercise of stock options	$ 2,141		2,141
Issuance of common stock for cash upon exercise of stock options, Shares	347,405	347,405
Vesting of restricted stock units		1,192,711
Share-based compensation expense	$ 32,016		32,016
Other comprehensive income (loss)	3,223			3,223
Net loss	(105,511)				(105,509)	(2)
Ending Balance at Jun. 30, 2023	395,967	$ 14	1,421,506	(893)	(1,024,591)	(69)
Ending Balance, Shares at Jun. 30, 2023		144,645,118
Beginning Balance at Mar. 31, 2023	423,952	$ 14	1,402,692	(1,905)	(976,781)	(68)
Beginning Balance, Shares at Mar. 31, 2023		144,279,969
Issuance of common stock for cash upon exercise of stock options	1,469		1,469
Issuance of common stock for cash upon exercise of stock options, Shares		201,647
Vesting of restricted stock units		163,502
Share-based compensation expense	17,345		17,345
Other comprehensive income (loss)	1,012			1,012
Net loss	(47,811)				(47,810)	(1)
Ending Balance at Jun. 30, 2023	$ 395,967	$ 14	$ 1,421,506	$ (893)	$ (1,024,591)	$ (69)
Ending Balance, Shares at Jun. 30, 2023		144,645,118

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Net loss	$ (105,511)	$ (114,880)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	10,234	9,409
Noncash lease expense	3,635	3,597
Share-based compensation expense	32,016	27,041
Intangible assets amortization	842	842
Investment amortization	(3,527)	1,414
Inventory reserve	757	2,769
Noncash interest expense	2,807
Other	65	(19)
Changes in operating assets and liabilities
Accounts receivable, net	8,464	(6,303)
Inventory	(6,542)	(2,284)
Prepaid expenses and other current assets	366	644
Accounts payable and accrued liabilities	(7,938)	(8,956)
Operating lease right-of-use assets and liabilities	(4,462)	(715)
Deferred revenue	(13,902)	(24,174)
Other	(12)	97
Net cash used in operating activities	(82,708)	(111,518)
Investing activities
Purchases of property and equipment	(6,621)	(8,375)
Purchases of marketable securities	(188,479)	(85,191)
Proceeds from maturities of marketable securities	295,402	136,000
Net cash provided by investing activities	100,302	42,434
Financing activities
Proceeds from exercise of stock options	2,141	6,739
Net cash provided by financing activities	2,141	6,739
Net increase (decrease) in cash, cash equivalents and restricted cash	19,735	(62,345)
Cash, cash equivalents and restricted cash at beginning of year	92,428	141,203
Cash, cash equivalents and restricted cash at end of period	112,163	78,858
Noncash investing activities
Purchases of equipment included in accounts payable and accrued liabilities	1,291	$ 3,286
Supplemental disclosure of cash flow information
Cash paid for interest	$ 4,642

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Adaptive Biotechnologies Corporation (“we,” “us” or “our”) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer and autoimmune disorders. We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Basis of Presentation and Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have 70 % ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the unaudited condensed consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the “Purchase Agreement”) that we entered into in September 2022, the provision for income taxes, including related reserves, and the analysis of goodwill impairment, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. Unaudited Interim Condensed Consolidated Financial Statements In our opinion, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state our financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments were of a normal, recurring nature. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) on February 14, 2023. Restricted Cash We had a restricted cash balance of $ 2.9 million and $ 2.4 million as of June 30, 2023 and December 31, 2022, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases. Concentrations of Risk We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, United States (“U.S.”) government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions. Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each condensed consolidated balance sheet date presented, respectively. For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: Revenue Accounts Receivable, Net Three Months Ended June 30, Six Months Ended June 30, June 30, December 31, 2023 2022 2023 2022 2023 2022 Customer A *% *% *% *% *% 15.8 % Customer B * 12.3 * 14.9 * 19.5 Genentech, Inc. and Roche Group 37.7 34.8 32.9 34.3 * * * less than 10% Revenue Recognition For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation. We derive revenue by providing diagnostic and research services in our Immune Medicine and Minimal Residual Disease (“MRD”) market opportunities. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, immunoSEQ, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (“Genentech”) and other biopharmaceutical customers in areas of drug and target discovery; and (3) providing our T-Detect COVID tests to clinical customers. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. For research customers who utilize either immunoSEQ or our MRD services, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: (1) the delivery of our immunoSEQ or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered. For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience. Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing. The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers’ achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers’ therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customers’ registrational trials, developing analytical plans for our data, participating on joint research committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers’ control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue We disaggregate our revenue from contracts with customers by market opportunity and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table presents our disaggregated revenue for the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Immune Medicine revenue Service revenue $ 5,508 $ 7,296 $ 12,610 $ 14,409 Collaboration revenue 17,536 15,082 26,654 28,785 Total Immune Medicine revenue 23,044 22,378 39,264 43,194 MRD revenue Service revenue 25,882 20,282 47,309 35,086 Regulatory milestone revenue — 1,000 — 4,000 Total MRD revenue 25,882 21,282 47,309 39,086 Total revenue $ 48,926 $ 43,660 $ 86,573 $ 82,280 During the three months ended June 30, 2023, we recognized $ 1.3 million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and from a change in estimate of total samples to be provided under certain of our agreements. During the three months ended June 30, 2022, we recognized $ 1.4 million in MRD service revenue related to a change in estimate of total samples to be provided under certain of our agreements and Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote. During the six months ended June 30, 2023, we recognized $ 2.7 million in revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled customer contracts and a change in estimate of total samples to be provided under certain of our agreements, $ 0.4 million of which was recognized as Immune Medicine service revenue and $ 2.3 million of which was recognized as MRD service revenue. During the six months ended June 30, 2022, we recognized $ 2.8 million in revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, changes in estimates of total samples to be provided under certain of our agreements and cancelled customer contracts, $ 0.2 million of which was recognized as Immune Medicine service revenue and $ 2.6 million of which was recognized as MRD service revenue. As of June 30, 2023, we could receive up to an additional $ 399.5 million in milestone payments in future periods if certain regulatory approvals are obtained by our customers’ therapeutics in connection with MRD data generated from our MRD product. Genentech Collaboration Agreement In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (the “Genentech Agreement”) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $ 300.0 million in February 2019 and may be eligible to receive more than $ 1.8 billion over time, including payments of up to $ 75.0 million upon the achievement of specified regulatory milestones ($ 10.0 million of which was achieved in the three months ended June 30, 2023), up to $ 300.0 million upon the achievement of specified development milestones and up to $ 1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the Genentech Agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use T cell receptors (“TCRs”) screened by our immune medicine platform to engineer and manufacture cellular medicines: • Shared Products. The shared products will use “off-the-shelf” TCRs identified against cancer antigens shared among patients (“Shared Products”). • Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (“Personalized Product”). Under the terms of the Genentech Agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements (“ASC 808”), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity’s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) to account for the activities related to the Genentech Agreement. In applying ASC 606, we identified the following performance obligations at the inception of the agreement: 1. License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. 2. License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. 3. License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. 4. License to existing shared antigen data packages. 5. Research and development services for Shared Products development, including expansion of shared antigen data packages. 6. Research and development services for private product development. 7. Obligations to participate on various joint research, development and project committees. We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech’s control of product commercialization. Specifically, under the Genentech Agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway. Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties. We determined the initial transaction price shall be made up of only the $ 300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the initial transaction price. In May 2023, one of the regulatory milestones was achieved, resulting in a $ 10.0 million addition to the transaction price, $ 7.7 million of which was recognized as revenue in the three months ended June 30, 2023 and $ 2.3 million of which was added to deferred revenue. We continue to exclude the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur. As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and are included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately eight to nine years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known. In total, we recognized $ 17.5 million and $ 13.8 million in Immune Medicine collaboration revenue during the three months ended June 30, 2023 and 2022, respectively, and $ 26.7 million and $ 26.0 million in Immune Medicine collaboration revenue during the six months ended June 30, 2023 and 2022, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.

Deferred Revenue

Deferred Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Deferred Revenue	4. Deferred Revenue Deferred revenue from the Genentech Agreement represents $ 23.0 million and $ 47.7 million of the current and non-current deferred revenue balances, respectively, as of June 30, 2023 and $ 31.8 million and $ 55.5 million of the current and non-current deferred revenue balances, respectively, as of December 31, 2022. We expect our current deferred revenue to be recognized as revenue within 12 months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately four years from June 30, 2023. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on various research and development activities. Changes in deferred revenue during the six months ended June 30, 2023 were as follows (in thousands): Deferred revenue balance at December 31, 2022 $ 122,714 Additions to deferred revenue during the period 22,462 Revenue recognized during the period ( 36,364 ) Deferred revenue balance at June 30, 2023 $ 108,812 As of June 30, 2023, $ 28.7 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2022.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements The following tables set forth the fair values of financial assets as of June 30, 2023 and December 31, 2022 that were measured at fair value on a recurring basis (in thousands): June 30, 2023 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 73,986 $ — $ — $ 73,986 U.S. government treasury and agency securities — 314,967 — 314,967 Total financial assets $ 73,986 $ 314,967 $ — $ 388,953 December 31, 2022 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 38,502 $ — $ — $ 38,502 Commercial paper — 9,969 — 9,969 U.S. government treasury securities — 385,848 — 385,848 Corporate bonds — 12,349 — 12,349 Total financial assets $ 38,502 $ 408,166 $ — $ 446,668 Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government treasury and agency securities, corporate bonds and commercial paper, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Of the June 30, 2023 Level 2 U.S. government treasury and agency securities balance, $ 7.0 million is recorded as cash and cash equivalents on our unaudited condensed consolidated balance sheet.

Investments

Investments	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	6. Investments Available-for-sale investments consisted of the following as of June 30, 2023 and December 31, 2022 (in thousands): June 30, 2023 Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Short-term marketable securities U.S. government treasury and agency securities $ 308,885 $ 12 $ ( 907 ) $ 307,990 Total short-term marketable securities $ 308,885 $ 12 $ ( 907 ) $ 307,990 December 31, 2022 Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Short-term marketable securities Commercial paper $ 9,969 $ — $ — $ 9,969 U.S. government treasury securities 389,898 14 ( 4,064 ) 385,848 Corporate bonds 12,415 — ( 66 ) 12,349 Total short-term marketable securities $ 412,282 $ 14 $ ( 4,130 ) $ 408,166 All the U.S. government treasury and agency securities, corporate bonds and commercial paper designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective condensed consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective condensed consolidated balance sheet date. Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of $ 0.9 million and $ 0.8 million were presented separately within the prepaid expenses and other current assets balance on the unaudited condensed consolidated balance sheet as of June 30, 2023 and on the condensed consolidated balance sheet as of December 31, 2022, respectively. The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of June 30, 2023 (in thousands): Less Than 12 Months 12 Months Or Greater Fair Value Unrealized Loss Fair Value Unrealized Loss U.S. government treasury and agency securities $ 199,578 $ ( 250 ) $ 67,989 $ ( 657 ) Total available-for-sale securities $ 199,578 $ ( 250 ) $ 67,989 $ ( 657 ) We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data. As of June 30, 2023, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of June 30, 2023 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Lessee Disclosure [Abstract]
Leases	7. Leases We have operating lease agreements for laboratory, office and warehouse facilities in Seattle, Washington, Bothell, Washington, South San Francisco, California and New York City, New York. As of June 30, 2023, we were not party to any finance leases. The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance as of June 30, 2023 (in thousands): 2023 (excluding the six months ended June 30, 2023) $ 7,065 2024 13,692 2025 14,098 2026 12,330 2027 11,944 Thereafter 69,244 Total undiscounted lease payments 128,373 Less: Imputed interest rate ( 24,852 ) Total operating lease liabilities 103,521 Less: Current portion ( 9,345 ) Operating lease liabilities, less current portion $ 94,176 During the six months ended June 30, 2023, cash paid for amounts included in the measurement of lease liabilities was $ 6.9 million. During the six months ended June 30, 2022, cash paid for amounts included in the measurement of lease liabilities was $ 3.3 million, net of $ 4.0 million of cash received for tenant improvement allowances. We have $ 2.1 million in letters of credit with one of our financial institutions in connection with certain of our leases.

Revenue Interest Purchase Agree

Revenue Interest Purchase Agreement	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue Interest Purchase Agreement	8. Revenue Interest Purchase Agreement In September 2022, we entered into the Purchase Agreement with OrbiMed Royalty & Credit Opportunities IV, LP (“OrbiMed”), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the “Purchasers”). Pursuant to the Purchase Agreement, we received $ 125.0 million from the Purchasers at closing, less certain transaction expenses. We are also entitled to receive up to $ 125.0 million in subsequent installments as follows: (i) $ 75 .0 million upon our request occurring no later than September 12, 2025 and (ii) $ 50.0 million upon our request in connection with certain permitted acquisitions occurring no later than September 12, 2025 , in each case subject to certain funding conditions. As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the “Revenue Interests”) from us based on a percentage of all GAAP revenue. Payments in respect of the Revenue Interests shall be made quarterly within 45 days following the end of each fiscal quarter (each, a “Revenue Interest Payment”). Accounting Treatment We accounted for the transaction as long-term debt recorded at amortized cost using the effective interest rate method. To determine the amortization of the Purchase Agreement obligation, we are required to estimate the amount and timing of future Revenue Interest Payments based on our estimate of the timing and amount of future revenues and calculate an effective interest rate which will amortize the obligation to zero over the amortization period. The calculated effective interest rate as of June 30, 2023 was 11.4 %. In connection with the Purchase Agreement, we incurred debt issuance costs of $ 0.6 million. Debt issuance costs have been recorded to long-term debt and are being amortized over the estimated term of the debt using the effective interest method, adjusted on a prospective basis for changes in the underlying assumptions and inputs. The assumptions used in determining the expected repayment term of the obligation and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. We periodically assess the amount and timing of expected Revenue Interest Payments based on internal forecasts. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the revenue interest liability and the effective interest rate. The following table sets forth the revenue interest liability, net activity during the six months ended June 30, 2023 (in thousands): Revenue interest liability, net at December 31, 2022 $ 125,360 Interest expense 3,531 Revenue interest payable ( 1,883 ) Revenue interest liability, net at March 31, 2023 127,008 Interest expense 3,605 Revenue interest payable ( 2,446 ) Revenue interest liability, net at June 30, 2023 $ 128,167 The revenue interest payable of $ 2.4 million was included within the accounts payable balance on the unaudited condensed consolidated balance sheet as of June 30, 2023.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Legal Proceedings We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of June 30, 2023. Indemnification Agreements In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Shareholders' Equity	10. Shareholders’ Equity Common Stock Our common stock has no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held . The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time. Our 2019 Equity Incentive Plan (“2019 Plan”) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5 % of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors. Furthermore, our Employee Stock Purchase Plan (“ESPP”) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1 % of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors. Effective January 1, 2023, our 2019 Plan and ESPP reserves increased by 7,155,250 shares and 1,431,050 shares, respectively. As of June 30, 2023, we had reserved shares of common stock for the following: Shares issuable upon the exercise of outstanding stock options granted 14,129,987 Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned 12,655,325 Shares available for future grant under the 2019 Equity Incentive Plan 13,408,783 Shares available for future grant under the Employee Stock Purchase Plan 4,235,348 Total shares of common stock reserved for future issuance 44,429,443

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	11. Equity Incentive Plans 2009 Equity Incentive Plan We adopted an equity incentive plan in 2009 (“2009 Plan”) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Stock options granted under this plan expire no later than ten years from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding stock options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While no shares are available for future grant under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder. 2019 Equity Incentive Plan The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of stock options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the stock option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, stock options granted under this plan expire no later than ten years from the grant date and vesting is established at the time of grant. Except for certain stock option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a four-year period, subject to continuous service through each applicable vesting date. As of June 30, 2023, we had 35,014,382 shares of common stock authorized for issuance under the 2019 Plan. Changes in shares available for grant during the six months ended June 30, 2023 were as follows: Shares Available for Grant Shares available for grant at December 31, 2022 14,581,975 2019 Equity Incentive Plan reserve increase effective January 1, 2023 7,155,250 Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned ( 9,749,483 ) Stock options and restricted stock units forfeited or expired 1,421,041 Shares available for grant at June 30, 2023 13,408,783 Stock Options Stock option activity under the 2009 Plan and 2019 Plan during the six months ended June 30, 2023 was as follows: Shares Subject to Weighted-Average Exercise Aggregate Intrinsic Value Stock options outstanding at December 31, 2022 13,520,997 $ 16.88 Stock options granted 1,612,032 8.46 Stock options forfeited ( 502,667 ) 17.43 Stock options expired ( 152,970 ) 30.78 Stock options exercised ( 347,405 ) 6.16 Stock options outstanding at June 30, 2023 14,129,987 $ 16.01 $ 2,377 Stock options vested and exercisable at June 30, 2023 8,872,007 $ 15.67 $ 2,377 The weighted-average remaining contractual life for stock options outstanding as of June 30, 2023 was 6.7 years. The weighted-average remaining contractual life for vested and exercisable stock options as of June 30, 2023 was 5.5 years. Restricted Stock Units Restricted stock unit activity under the 2019 Plan during the six months ended June 30, 2023 was as follows: Restricted Stock Units Weighted-Average Grant Date Nonvested restricted stock units outstanding at December 31, 2022 5,981,755 $ 14.11 Restricted stock units granted 6,719,011 8.39 Restricted stock units forfeited ( 765,404 ) 11.75 Restricted stock units vested ( 1,192,711 ) 14.51 Nonvested restricted stock units outstanding at June 30, 2023 10,742,651 $ 10.65 Market-Based Restricted Stock Units In addition to the restricted stock units described above, our board of directors approved awards of market-based restricted stock units to our chief executive officer and chief scientific officer in March 2023. The shares of common stock that may be earned under the awards, each ranging from zero shares to 709,220 shares, are calculated based upon our total shareholder return during a three-year performance period as measured against that of the group of companies comprising the S&P Biotechnology Select Industry Index as of the grant date, subject to certain adjustments to such index group. Except as expressly provided in the terms of each award's agreement, vesting is subject to the respective grantee's continuous service through the end of the three-year performance period. These market-based restricted stock units, along with those granted to our chief executive officer in March 2022, under which zero shares to 494,234 shares may be earned, remain outstanding as of June 30, 2023. Grant Date Fair Value of Stock Options, Restricted Stock Units and Market-Based Restricted Stock Units Granted The estimated grant date fair values of stock options granted during the six months ended June 30, 2023 and 2022 were estimated using the Black-Scholes option-pricing model with the following assumptions: Six Months Ended June 30, 2023 2022 Fair value of common stock $ 8.46 $ 7.30 - $ 14.95 Expected term (in years) 5.27 - 6.08 5.27 - 6.08 Risk-free interest rate 4.2 % - 4.3 % 1.7 % - 3.0 % Expected volatility 71.2 % - 71.6 % 68.2 % - 71.0 % Expected dividend yield — — The determination of the grant date fair value of stock options granted using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require judgment to determine. The valuation assumptions were determined as follows: Fair value of common stock— The fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. Expected term —The expected term of stock options granted to employees and non-employee directors is determined using the “simplified” method, as illustrated in ASC Topic 718, Compensation—Stock Compensation , as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is based on the midpoint between the vesting date and the end of the contractual term of the stock option. Risk-free interest rate —We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the stock options. Expected volatility —As we do not have sufficient trading history for our common stock, expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term. Expected dividend yield —We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model. The weighted-average grant date fair value per share of stock options granted during the six months ended June 30, 2023 and 2022 was $ 5.61 and $ 7.36 , respectively. The grant date fair value of restricted stock units granted is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. The weighted-average grant date fair value per share of restricted stock units granted during the six months ended June 30, 2023 and 2022 was $ 8.39 and $ 11.66 , respectively. The weighted-average grant date fair value per share of the market-based restricted stock units granted during the six months ended June 30, 2023 and 2022 was $ 13.82 and $ 18.89 , respectively, and was determined using a Monte Carlo valuation model, which uses assumptions such as volatility, risk-free interest rate and dividend estimated for the respective performance periods. The weighted-average grant date fair value per share of the target payout level of the market-based restricted stock units outstanding as of June 30, 2023, 956,337 shares, was $ 15.13 . The aggregate share-based compensation expense of the market-based restricted stock units granted during the six months ended June 30, 2023 and 2022 was $ 9.8 million and $ 4.7 million, respectively, and is recognized on a straight-line basis over the respective grants' three-year performance periods, which are also the requisite service periods. Attainment of each grant's respective market condition and the number of shares earned and vested does not impact the related share-based compensation expense recognized. Share-based compensation expense will be reversed only if the respective grantee does not provide continuous service through the respective performance period for reasons other than those expressly provided in the terms of the respective award. The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the three and six months ended June 30, 2023 and 2022, respectively, are included on the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of revenue $ 1,061 $ 954 $ 2,355 $ 1,749 Research and development 5,531 4,643 10,080 8,988 Sales and marketing 4,439 3,584 7,870 6,813 General and administrative 6,314 4,999 11,711 9,491 Total share-based compensation expense $ 17,345 $ 14,180 $ 32,016 $ 27,041 As of June 30, 2023, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows: Unrecognized Share-Based Remaining Weighted-Average Nonvested stock options $ 52,974 2.27 Nonvested restricted stock units 101,404 3.11 Nonvested market-based restricted stock units 11,373 2.45

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders	12. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2023 and 2022, respectively (in thousands, except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Net loss attributable to Adaptive Biotechnologies Corporation $ ( 47,810 ) $ ( 52,046 ) $ ( 105,509 ) $ ( 114,782 ) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 144,397,693 142,363,589 143,956,867 142,032,261 Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ ( 0.33 ) $ ( 0.37 ) $ ( 0.73 ) $ ( 0.81 ) Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2023 and 2022, respectively, as they had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock options outstanding 14,556,602 14,693,276 14,180,632 13,978,339 Nonvested restricted stock units outstanding 11,007,405 5,364,447 8,956,361 3,983,640 Maximum nonvested market-based restricted stock units outstanding eligible to be earned 1,912,674 494,234 1,411,126 324,938 Total 27,476,681 20,551,957 24,548,119 18,286,917

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have 70 % ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the unaudited condensed consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the “Purchase Agreement”) that we entered into in September 2022, the provision for income taxes, including related reserves, and the analysis of goodwill impairment, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.
Unaudited Interim Condensed Consolidated Financial Statements	Unaudited Interim Condensed Consolidated Financial Statements In our opinion, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state our financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments were of a normal, recurring nature. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) on February 14, 2023.
Restricted Cash	Restricted Cash We had a restricted cash balance of $ 2.9 million and $ 2.4 million as of June 30, 2023 and December 31, 2022, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases.
Concentrations of Risk	Concentrations of Risk We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, United States (“U.S.”) government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions. Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each condensed consolidated balance sheet date presented, respectively. For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: Revenue Accounts Receivable, Net Three Months Ended June 30, Six Months Ended June 30, June 30, December 31, 2023 2022 2023 2022 2023 2022 Customer A *% *% *% *% *% 15.8 % Customer B * 12.3 * 14.9 * 19.5 Genentech, Inc. and Roche Group 37.7 34.8 32.9 34.3 * * * less than 10%
Revenue Recognition	Revenue Recognition For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation. We derive revenue by providing diagnostic and research services in our Immune Medicine and Minimal Residual Disease (“MRD”) market opportunities. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, immunoSEQ, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (“Genentech”) and other biopharmaceutical customers in areas of drug and target discovery; and (3) providing our T-Detect COVID tests to clinical customers. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. For research customers who utilize either immunoSEQ or our MRD services, contracts typically include an amount billed in advance of services (“upfront”) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: (1) the delivery of our immunoSEQ or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the remaining samples expected to be delivered. For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience. Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient’s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient’s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient’s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing. The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers’ achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers’ therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customers’ registrational trials, developing analytical plans for our data, participating on joint research committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers’ own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers’ control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Concentrations of Risk Percentage	For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: Revenue Accounts Receivable, Net Three Months Ended June 30, Six Months Ended June 30, June 30, December 31, 2023 2022 2023 2022 2023 2022 Customer A *% *% *% *% *% 15.8 % Customer B * 12.3 * 14.9 * 19.5 Genentech, Inc. and Roche Group 37.7 34.8 32.9 34.3 * * * less than 10%

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregated Revenue	The following table presents our disaggregated revenue for the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Immune Medicine revenue Service revenue $ 5,508 $ 7,296 $ 12,610 $ 14,409 Collaboration revenue 17,536 15,082 26,654 28,785 Total Immune Medicine revenue 23,044 22,378 39,264 43,194 MRD revenue Service revenue 25,882 20,282 47,309 35,086 Regulatory milestone revenue — 1,000 — 4,000 Total MRD revenue 25,882 21,282 47,309 39,086 Total revenue $ 48,926 $ 43,660 $ 86,573 $ 82,280

Deferred Revenue (Tables)

Deferred Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Changes in Deferred Revenue	Changes in deferred revenue during the six months ended June 30, 2023 were as follows (in thousands): Deferred revenue balance at December 31, 2022 $ 122,714 Additions to deferred revenue during the period 22,462 Revenue recognized during the period ( 36,364 ) Deferred revenue balance at June 30, 2023 $ 108,812

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables set forth the fair values of financial assets as of June 30, 2023 and December 31, 2022 that were measured at fair value on a recurring basis (in thousands): June 30, 2023 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 73,986 $ — $ — $ 73,986 U.S. government treasury and agency securities — 314,967 — 314,967 Total financial assets $ 73,986 $ 314,967 $ — $ 388,953 December 31, 2022 Level 1 Level 2 Level 3 Total Financial assets Money market funds $ 38,502 $ — $ — $ 38,502 Commercial paper — 9,969 — 9,969 U.S. government treasury securities — 385,848 — 385,848 Corporate bonds — 12,349 — 12,349 Total financial assets $ 38,502 $ 408,166 $ — $ 446,668

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-sale Investments	Available-for-sale investments consisted of the following as of June 30, 2023 and December 31, 2022 (in thousands): June 30, 2023 Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Short-term marketable securities U.S. government treasury and agency securities $ 308,885 $ 12 $ ( 907 ) $ 307,990 Total short-term marketable securities $ 308,885 $ 12 $ ( 907 ) $ 307,990 December 31, 2022 Amortized Cost Unrealized Gain Unrealized Loss Estimated Fair Value Short-term marketable securities Commercial paper $ 9,969 $ — $ — $ 9,969 U.S. government treasury securities 389,898 14 ( 4,064 ) 385,848 Corporate bonds 12,415 — ( 66 ) 12,349 Total short-term marketable securities $ 412,282 $ 14 $ ( 4,130 ) $ 408,166
Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position	The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of June 30, 2023 (in thousands): Less Than 12 Months 12 Months Or Greater Fair Value Unrealized Loss Fair Value Unrealized Loss U.S. government treasury and agency securities $ 199,578 $ ( 250 ) $ 67,989 $ ( 657 ) Total available-for-sale securities $ 199,578 $ ( 250 ) $ 67,989 $ ( 657 )

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Lessee Disclosure [Abstract]
Summary of Reconciles Undiscounted Operating Lease Cash Flows	The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance as of June 30, 2023 (in thousands): 2023 (excluding the six months ended June 30, 2023) $ 7,065 2024 13,692 2025 14,098 2026 12,330 2027 11,944 Thereafter 69,244 Total undiscounted lease payments 128,373 Less: Imputed interest rate ( 24,852 ) Total operating lease liabilities 103,521 Less: Current portion ( 9,345 ) Operating lease liabilities, less current portion $ 94,176

Revenue Interest Purchase Agr_2

Revenue Interest Purchase Agreement (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenue Interest Liability, Net Activity	The following table sets forth the revenue interest liability, net activity during the six months ended June 30, 2023 (in thousands): Revenue interest liability, net at December 31, 2022 $ 125,360 Interest expense 3,531 Revenue interest payable ( 1,883 ) Revenue interest liability, net at March 31, 2023 127,008 Interest expense 3,605 Revenue interest payable ( 2,446 ) Revenue interest liability, net at June 30, 2023 $ 128,167

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Summary of Reserved Shares of Common Stock	As of June 30, 2023, we had reserved shares of common stock for the following: Shares issuable upon the exercise of outstanding stock options granted 14,129,987 Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned 12,655,325 Shares available for future grant under the 2019 Equity Incentive Plan 13,408,783 Shares available for future grant under the Employee Stock Purchase Plan 4,235,348 Total shares of common stock reserved for future issuance 44,429,443

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Changes in Shares Available for Grant	Changes in shares available for grant during the six months ended June 30, 2023 were as follows: Shares Available for Grant Shares available for grant at December 31, 2022 14,581,975 2019 Equity Incentive Plan reserve increase effective January 1, 2023 7,155,250 Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned ( 9,749,483 ) Stock options and restricted stock units forfeited or expired 1,421,041 Shares available for grant at June 30, 2023 13,408,783
Summary of Stock Option Activity Under 2009 Plan and 2019 Plan	Stock option activity under the 2009 Plan and 2019 Plan during the six months ended June 30, 2023 was as follows: Shares Subject to Weighted-Average Exercise Aggregate Intrinsic Value Stock options outstanding at December 31, 2022 13,520,997 $ 16.88 Stock options granted 1,612,032 8.46 Stock options forfeited ( 502,667 ) 17.43 Stock options expired ( 152,970 ) 30.78 Stock options exercised ( 347,405 ) 6.16 Stock options outstanding at June 30, 2023 14,129,987 $ 16.01 $ 2,377 Stock options vested and exercisable at June 30, 2023 8,872,007 $ 15.67 $ 2,377
Summary of Restricted Stock Unit Activity	Restricted stock unit activity under the 2019 Plan during the six months ended June 30, 2023 was as follows: Restricted Stock Units Weighted-Average Grant Date Nonvested restricted stock units outstanding at December 31, 2022 5,981,755 $ 14.11 Restricted stock units granted 6,719,011 8.39 Restricted stock units forfeited ( 765,404 ) 11.75 Restricted stock units vested ( 1,192,711 ) 14.51 Nonvested restricted stock units outstanding at June 30, 2023 10,742,651 $ 10.65
Summary of Estimated Grant Date Fair Value of Stock Options Granted	The estimated grant date fair values of stock options granted during the six months ended June 30, 2023 and 2022 were estimated using the Black-Scholes option-pricing model with the following assumptions: Six Months Ended June 30, 2023 2022 Fair value of common stock $ 8.46 $ 7.30 - $ 14.95 Expected term (in years) 5.27 - 6.08 5.27 - 6.08 Risk-free interest rate 4.2 % - 4.3 % 1.7 % - 3.0 % Expected volatility 71.2 % - 71.6 % 68.2 % - 71.0 % Expected dividend yield — —
Summary of Compensation Costs Related to Stock Options and RSUs Included on Unaudited Condensed Consolidated Statements of Operations	The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the three and six months ended June 30, 2023 and 2022, respectively, are included on the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of revenue $ 1,061 $ 954 $ 2,355 $ 1,749 Research and development 5,531 4,643 10,080 8,988 Sales and marketing 4,439 3,584 7,870 6,813 General and administrative 6,314 4,999 11,711 9,491 Total share-based compensation expense $ 17,345 $ 14,180 $ 32,016 $ 27,041
Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period	As of June 30, 2023, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows: Unrecognized Share-Based Remaining Weighted-Average Nonvested stock options $ 52,974 2.27 Nonvested restricted stock units 101,404 3.11 Nonvested market-based restricted stock units 11,373 2.45

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders	The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2023 and 2022, respectively (in thousands, except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Net loss attributable to Adaptive Biotechnologies Corporation $ ( 47,810 ) $ ( 52,046 ) $ ( 105,509 ) $ ( 114,782 ) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 144,397,693 142,363,589 143,956,867 142,032,261 Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ ( 0.33 ) $ ( 0.37 ) $ ( 0.73 ) $ ( 0.81 )
Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share	The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2023 and 2022, respectively, as they had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock options outstanding 14,556,602 14,693,276 14,180,632 13,978,339 Nonvested restricted stock units outstanding 11,007,405 5,364,447 8,956,361 3,983,640 Maximum nonvested market-based restricted stock units outstanding eligible to be earned 1,912,674 494,234 1,411,126 324,938 Total 27,476,681 20,551,957 24,548,119 18,286,917

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Significant Accounting Policies [Line Items]
Restricted cash	$ 2,923	$ 2,398
Digital Biotechnologies Inc
Significant Accounting Policies [Line Items]
Ownership interest percentage	70%

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) - Customer Concentration Risk	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Customer A | Accounts Receivable, Net
Significant Accounting Policies [Line Items]
Concentration risk, percentage					15.80%
Customer B | Revenue
Significant Accounting Policies [Line Items]
Concentration risk, percentage		12.30%		14.90%
Customer B | Accounts Receivable, Net
Significant Accounting Policies [Line Items]
Concentration risk, percentage					19.50%
Genentech, Inc. and Roche Group | Revenue
Significant Accounting Policies [Line Items]
Concentration risk, percentage	37.70%	34.80%	32.90%	34.30%

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Revenue	$ 48,926	$ 43,660	$ 86,573	$ 82,280
Immune Medicine Revenue
Disaggregation Of Revenue [Line Items]
Revenue	23,044	22,378	39,264	43,194
Immune Medicine Revenue | Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue	5,508	7,296	12,610	14,409
Immune Medicine Revenue | Collaboration Revenue
Disaggregation Of Revenue [Line Items]
Revenue	17,536	15,082	26,654	28,785
MRD Revenue
Disaggregation Of Revenue [Line Items]
Revenue	25,882	21,282	47,309	39,086
MRD Revenue | Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue	$ 25,882	20,282	$ 47,309	35,086
MRD Revenue | Regulatory Milestone Revenue
Disaggregation Of Revenue [Line Items]
Revenue		$ 1,000		$ 4,000

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	May 31, 2023	Feb. 28, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement			$ 48,926,000	$ 43,660,000	$ 86,573,000	$ 82,280,000
Deferred revenue			108,812,000		108,812,000		$ 122,714,000
Medicare Reimbursements
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement			1,300,000	1,400,000	2,700,000	2,800,000
Medicare Reimbursements | Immune Medicine Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement					400,000	200,000
Medicare Reimbursements | MRD Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement					2,300,000	2,600,000
MRD Development Agreements | Maximum
Disaggregation Of Revenue [Line Items]
Additional milestone payment receivable			399,500,000		399,500,000
Genentech Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement	$ 7,700,000		17,500,000	$ 13,800,000	26,700,000	$ 26,000,000
Non-refundable upfront payments received		$ 300,000,000			$ 300,000,000
Additional transaction price of regulatory milestone	10,000,000
Deferred revenue	$ 2,300,000
Genentech Collaboration Agreement | Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Additional transaction price of regulatory milestone			10,000,000
Genentech Collaboration Agreement | Maximum
Disaggregation Of Revenue [Line Items]
Revenue recognition expected period					9 years
Genentech Collaboration Agreement | Maximum | Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			75,000,000		$ 75,000,000
Genentech Collaboration Agreement | Maximum | Development Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			300,000,000		300,000,000
Genentech Collaboration Agreement | Maximum | Commercial Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			1,430,000,000		1,430,000,000
Genentech Collaboration Agreement | Minimum
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			$ 1,800,000,000		$ 1,800,000,000
Revenue recognition expected period					8 years

Deferred Revenue - Additional I

Deferred Revenue - Additional Information (Details) - USD ($) $ in Thousands		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Current deferred revenue	$ 57,917	$ 57,917	$ 64,115
Non-current deferred revenue	50,895	50,895	58,599
Revenue recognized	28,700	(36,364)
Development Revenue | Genentech, Inc.
Disaggregation Of Revenue [Line Items]
Current deferred revenue	23,000	23,000	31,800
Non-current deferred revenue	$ 47,700	$ 47,700	$ 55,500

Deferred Revenue - Additional_2

Deferred Revenue - Additional Information (Details1) - Genentech, Inc. - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-07-01	Jun. 30, 2023
Disaggregation Of Revenue [Line Items]
Deferred revenue, expected to be recognized	12 months
Maximum
Disaggregation Of Revenue [Line Items]
Deferred revenue, expected to be recognized	4 years

Deferred Revenue - Schedule of

Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) - USD ($) $ in Thousands		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Deferred revenue balance at December 31, 2022		$ 122,714
Additions to deferred revenue during the period		22,462
Revenue recognized during the period	$ 28,700	(36,364)
Deferred revenue balance at June 30, 2023	$ 108,812	$ 108,812

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Financial assets
Total financial assets	$ 388,953	$ 446,668
Level 1
Financial assets
Total financial assets	73,986	38,502
Level 2
Financial assets
Total financial assets	314,967	408,166
Money Market Funds
Financial assets
Total financial assets	73,986	38,502
Money Market Funds | Level 1
Financial assets
Total financial assets	73,986	38,502
U.S. Government Treasury and Agency Securities
Financial assets
Total financial assets	314,967
U.S. Government Treasury and Agency Securities | Level 2
Financial assets
Total financial assets	$ 314,967
Commercial Paper
Financial assets
Total financial assets		9,969
Commercial Paper | Level 2
Financial assets
Total financial assets		9,969
U.S. Government Treasury Securities
Financial assets
Total financial assets		385,848
U.S. Government Treasury Securities | Level 2
Financial assets
Total financial assets		385,848
Corporate Bonds
Financial assets
Total financial assets		12,349
Corporate Bonds | Level 2
Financial assets
Total financial assets		$ 12,349

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Millions	Jun. 30, 2023 USD ($)
U.S. Government Treasury and Agency Securities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 7

Investments - Schedule of Avail

Investments - Schedule of Available-for-sale Investments (Details) - Short-Term Marketable Securities - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	$ 308,885	$ 412,282
Unrealized Gain	12	14
Unrealized Loss	(907)	(4,130)
Estimated Fair Value	307,990	408,166
U.S. Government Treasury and Agency Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost	308,885
Unrealized Gain	12
Unrealized Loss	(907)
Estimated Fair Value	$ 307,990
Commercial Paper
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost		9,969
Estimated Fair Value		9,969
U.S. Government Treasury Securities
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost		389,898
Unrealized Gain		14
Unrealized Loss		(4,064)
Estimated Fair Value		385,848
Corporate Bonds
Schedule of Available-for-Sale Securities [Line Items]
Amortized Cost		12,415
Unrealized Loss		(66)
Estimated Fair Value		$ 12,349

Investments - Additional Inform

Investments - Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Prepaid Expenses and Other Current Assets
Schedule of Available-for-Sale Securities [Line Items]
Accrued interest receivable	$ 0.9	$ 0.8

Investments - Schedule of Gross

Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Schedule of Available-for-Sale Securities [Line Items]
Less than 12 months, Fair value	$ 199,578
Less than 12 months, Unrealized loss	(250)
12 months or greater, Fair value	67,989
12 months or greater, Unrealized loss	(657)
U.S. Government Treasury and Agency Securities
Schedule of Available-for-Sale Securities [Line Items]
Less than 12 months, Fair value	199,578
Less than 12 months, Unrealized loss	(250)
12 months or greater, Fair value	67,989
12 months or greater, Unrealized loss	$ (657)

Leases - Summary of Reconciles

Leases - Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Lessee Disclosure [Abstract]
2023 (excluding the six months ended June 30, 2023)	$ 7,065
2024	13,692
2025	14,098
2026	12,330
2027	11,944
Thereafter	69,244
Total undiscounted lease payments	128,373
Less: Imputed interest rate	(24,852)
Total operating lease liabilities	103,521
Less: Current portion	(9,345)	$ (9,230)
Operating lease liabilities, less current portion	$ 94,176	$ 98,772

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Lessee Disclosure [Abstract]
Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received	$ 6.9	$ 3.3
Cash received for tenant improvement allowances		$ 4
Letter of credit	$ 2.1

Revenue Interest Purchase Agr_3

Revenue Interest Purchase Agreement - Additional Information (Details) - Purchase Agreement - OrbiMed - USD ($)		3 Months Ended		6 Months Ended
	Sep. 12, 2022	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received	$ 125,000,000
Potential revenue interest second payment to be received	$ 75,000,000
Purchase agreement, second payment date	Sep. 12, 2025
Potential revenue interest third payment to be received	$ 50,000,000
Purchase agreement, third payment date	Sep. 12, 2025
Revenue interest payment term	45 days
Amortization of purchase agreement obligation				$ 0
Effective interest rate		11.40%		11.40%
Debt issuance costs		$ 600,000		$ 600,000
Revenue interest payable		$ 2,446,000	$ 1,883,000	$ 2,400,000
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential revenue interest payment to be received	$ 125,000,000

Revenue Interest Purchase Agr_4

Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue interest liability, net		$ 125,360	$ 125,360
Revenue interest liability, net	$ 128,167		128,167
OrbiMed | Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue interest liability, net	127,008	125,360	125,360
Interest expense	3,605	3,531
Revenue interest payable	(2,446)	(1,883)	(2,400)
Revenue interest liability, net	$ 128,167	$ 127,008	$ 128,167

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details)			6 Months Ended
	Jan. 01, 2023 shares	Jan. 01, 2020	Jun. 30, 2023 Vote
Class Of Stock [Line Items]
Common stock voting rights description			Holders of our common stock are entitled to one vote for each share of common stock held
Number of vote for each share | Vote			1
Employee Stock Purchase Plan
Class Of Stock [Line Items]
Increase in share reserve	1,431,050
Employee Stock Purchase Plan | Maximum
Class Of Stock [Line Items]
Percentage of annual increases in number of shares		1%
2019 Equity Incentive Plan
Class Of Stock [Line Items]
Increase in share reserve	7,155,250
2019 Equity Incentive Plan | Maximum
Class Of Stock [Line Items]
Percentage of annual increases in number of shares		5%

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)	Jun. 30, 2023 shares
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	44,429,443
Shares Issuable Upon the Exercise of Outstanding Stock Options Granted
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	14,129,987
Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	12,655,325
Common Stock Options Granted | 2019 Equity Incentive Plan
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	13,408,783
Common Stock Options Granted | Employee Stock Purchase Plan
Class Of Stock [Line Items]
Total shares of common stock reserved for future issuance	4,235,348

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average remaining contractual life stock options outstanding			6 years 8 months 12 days
Weighted-average remaining contractual life vested and exercisable options outstanding			5 years 6 months
Weighted-average grant date fair value			$ 5.61	$ 7.36
Recognized share-based compensation expense	$ 17,345	$ 14,180	$ 32,016	$ 27,041
Option Valuation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield			0%
Monte Carlo Valuation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense			$ 9,800	$ 4,700
Requisite service period term			3 years
Market-Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units outstanding	956,337		956,337
Weighted-average grant date fair value per share	$ 15.13		$ 15.13
Market-Based Restricted Stock Units | Monte Carlo Valuation Model
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value			$ 13.82	$ 18.89
Market-Based Restricted Stock Units | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance period term			3 years
Market-Based Restricted Stock Units | Minimum | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock that may be earned under the award	0		0			0
Market-Based Restricted Stock Units | Maximum | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock that may be earned under the award	709,220		709,220			494,234
2009 Equity Incentive Plan | Grant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future issuance	0		0
2009 Equity Incentive Plan | Grant | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option expiration period			10 years
2019 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future issuance	13,408,783		13,408,783		14,581,975
2019 Equity Incentive Plan | Grant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for issuance	35,014,382		35,014,382
2019 Equity Incentive Plan | Grant | Non Employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
2019 Equity Incentive Plan | Grant | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option expiration period			10 years
2019 Equity Incentive Plan | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value			$ 8.39	$ 11.66
Restricted stock units outstanding	10,742,651		10,742,651		5,981,755
Weighted-average grant date fair value per share	$ 10.65		$ 10.65		$ 14.11

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) - 2019 Equity Incentive Plan	6 Months Ended
	Jun. 30, 2023 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for grant at December 31, 2022	14,581,975
2019 Equity Incentive Plan reserve increase effective January 1, 2023	7,155,250
Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned	(9,749,483)
Stock options and restricted stock units forfeited or expired	1,421,041
Shares available for grant at June 30, 2023	13,408,783

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance	13,520,997
Shares Subject to Outstanding Stock Options, Stock Options granted	1,612,032
Shares Subject to Outstanding Stock Options, Stock Options forfeited	(502,667)
Shares Subject to Outstanding Stock Options, Stock Options expired	(152,970)
Shares Subject to Outstanding Stock Options, Stock Options exercised	(347,405)
Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance	14,129,987
Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable	8,872,007
Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance	$ 16.88
Weighted Average Exercise Price per Share, Stock Options granted	8.46
Weighted Average Exercise Price per Share, Stock Options forfeited	17.43
Weighted Average Exercise Price per Share, Stock Options expired	30.78
Weighted Average Exercise Price per Share, Stock Options exercised	6.16
Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance	16.01
Weighted Average Exercise Price per Share, Stock Options vested and exercisable	$ 15.67
Aggregate Intrinsic Value, Stock Option outstanding	$ 2,377
Aggregate Intrinsic Value, Stock Options vested and exercisable	$ 2,377

Equity Incentive Plans - Summ_3

Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Weighted-Average Grant Date Fair Value per Share
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted	$ 5.61	$ 7.36
Restricted Stock Units (RSUs) | 2019 Equity Incentive Plan
Restricted Stock Units Outstanding
Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance	5,981,755
Restricted Stock Units Outstanding, Granted	6,719,011
Restricted Stock Units Outstanding, Forfeited	(765,404)
Restricted Stock Units Outstanding, Vested	(1,192,711)
Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance	10,742,651
Weighted-Average Grant Date Fair Value per Share
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance	$ 14.11
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted	8.39	$ 11.66
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited	11.75
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested	14.51
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance	$ 10.65

Equity Incentive Plans - Summ_4

Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Stock Options Granted (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 8.46
Risk-free interest rate, minimum	4.20%	1.70%
Risk-free interest rate, maximum	4.30%	3%
Expected volatility, minimum	71.20%	68.20%
Expected volatility, maximum	71.60%	71%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock		$ 7.3
Expected term (in years)	5 years 3 months 7 days	5 years 3 months 7 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock		$ 14.95
Expected term (in years)	6 years 29 days	6 years 29 days

Equity Incentive Plans - Summ_5

Equity Incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUs Included on Unaudited Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 17,345	$ 14,180	$ 32,016	$ 27,041
Cost of Revenue
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	1,061	954	2,355	1,749
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	5,531	4,643	10,080	8,988
Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	4,439	3,584	7,870	6,813
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 6,314	$ 4,999	$ 11,711	$ 9,491

Equity Incentive Plans - Schedu

Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Nonvested Stock Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Share-Based Compensation Expense	$ 52,974
Remaining Weighted-Average Recognition Period (in years)	2 years 3 months 7 days
Nonvested Restricted Stock Units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Share-Based Compensation Expense	$ 101,404
Remaining Weighted-Average Recognition Period (in years)	3 years 1 month 9 days
Nonvested Market-Based Restricted Stock Units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Share-Based Compensation Expense	$ 11,373
Remaining Weighted-Average Recognition Period (in years)	2 years 5 months 12 days

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss attributable to Adaptive Biotechnologies Corporation	$ (47,810)	$ (52,046)	$ (105,509)	$ (114,782)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	144,397,693	142,363,589	143,956,867	142,032,261
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	$ (0.33)	$ (0.37)	$ (0.73)	$ (0.81)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	144,397,693	142,363,589	143,956,867	142,032,261
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	$ (0.33)	$ (0.37)	$ (0.73)	$ (0.81)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	27,476,681	20,551,957	24,548,119	18,286,917
Common Stock Options Granted
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	14,556,602	14,693,276	14,180,632	13,978,339
Nonvested Restricted Stock Units Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	11,007,405	5,364,447	8,956,361	3,983,640
Nonvested Market-based Restricted Stock Units Outstanding Granted
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	1,912,674	494,234	1,411,126	324,938